CoChat

Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials

The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.

Abstract

Background Cancer anorexia-cachexia syndrome is associated with increased morbidity and mortality. Anamorelin is an oral ghrelin-receptor agonist with appetite-enhancing and anabolic activity. We assessed the effects of anamorelin on body composition, strength, quality of life, biochemical markers, and safety in patients with cancer anorexia-cachexia.Methods Data were pooled, a priori, from two completed phase 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurable cancer and weight loss of 5% or more. Patients were stratified by weight loss severity (5-15%, >15%) and randomly allocated (1:1) with a computer-generated randomisation schedule to anamorelin hydrochloride 50 mg or placebo once-daily for 12 weeks. Primary outcome was lean body mass by dual-energy x-ray absorptiometry over the 12 week treatment period in eligible patients who had at least one dose of study drug and post-treatment efficacy assessment. We assessed safety in all patients who received at least one dose of study drug. The trials are registered with ClinicalTrials.gov, numbers NCT00219817 and NCT00267358.Findings Between June 29, 2005, and Oct 26, 2006, we enrolled 44 patients in the anamorelin group and 38 patients in the placebo group. 74 patients were eligible for the efficacy analyses. Over 12 weeks, lean body mass increased in 38 patients in the anamorelin group by a least-squares mean of 1.89 kg (95% CI 0.84 to 2.95) compared with a decrease of a least-squares mean of -0.20 kg (-1.23 to 0.83) for 36 patients in the placebo group (difference 2.09 kg [0.94-3.25]; p=0.0006). 42 (95%) of 44 patients treated with anamorelin and 33 (87%) of 38 patients treated with placebo had adverse events. The most common grade 3-4 adverse events (treatment-related or not) in the anamorelin group were fatigue, asthenia, atrial fibrillation, and dyspnoea (two [5%] each); in the placebo group, such events were pneumonia (three [8%]) and anaemia, thrombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each).Interpretation Anamorelin treatment for 12 weeks had a favourable clinical response profile in patients with cancer anorexia-cachexia syndrome. These findings support further investigation in this setting.Funding Helsinn Therapeutics (US), Helsinn Healthcare SA.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(14)71154-4

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 221

Metadata

Authors
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J.
Affiliations
  • Michael E. DeBakey VA Medical Center (US)
  • Georgetown University (US)
  • Helsinn Therapeutics (United States) (US)
Corresponding author
Garcia, José M
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2015-01
Volume
16
Issue
1
Pages
108-116
ISSN
1470-2045 (ISSN-L)
OpenAlex
W1987892987
Cited by
218
References
38
Citations by year
2026: 11 · 2025: 13 · 2024: 15 · 2023: 17 · 2022: 8 · 2021: 19 · 2020: 14 · 2019: 21 · 2018: 23 · 2017: 30 · 2016: 28 · 2015: 17
FWCI
17.06
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Helsinn
  • Helsinn Therapeutics
  • National Institute on Aging (R03AG040583, AG040583, NIA T32AG000183, T32AG000183)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
Keywords
anamorelin, cancer cachexia, anorexia-cachexia syndrome, ghrelin receptor agonist, lean body mass, body composition, weight loss, advanced cancer, appetite, quality of life, muscle strength, adverse events, atrial fibrillation, fatigue, drug safety, pooled analysis of trials, anabolic activity
MeSH terms
Adult, Aged, Aged, 80 and over, Analysis of Variance, Body Composition, Cachexia, Female, Humans, Hydrazines, Male, Middle Aged, Neoplasms, Oligopeptides, Quality of Life, Time Factors, United States, Weight Gain, Absorptiometry, Photon, Least-Squares Analysis, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase II as Topic, Appetite Stimulants, Anabolic Agents, Muscle Strength, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. https://app.cochat.ai/papers/10.1016/s1470-2045(14)71154-4
The paper
Garcia, J. M., Boccia, R. V., Graham, C. D., Yan, Y., Duus, E. M., Allen, S., & Friend, J. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(14)71154-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.